Lynparza Poised To Bring Targeted Therapy To Prostate Cancer
The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.
You may also be interested in...
Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.
AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial data in metastatic castration-resistant prostate cancer, putting pressure on rival Clovis’s Rubraca.
The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.